Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07282574 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
MinorTrial sites expanded: 108 → 114 locationsEligibility criteria expanded, about 36 words · Secondary endpoints: details revised at 6 of 15 entriesShow 2 more changesShow less
Eligibility criteria expanded, about 36 words
Secondary endpoints: details revised at 6 of 15 entries
MinorTrial sites expanded: 103 → 108 locationsv10
MinorTrial sites expanded: 91 → 103 locationsv9
MinorTrial sites expanded: 73 → 91 locationsv8
MinorTrial sites expanded: 47 → 73 locationsv7
MinorTrial sites expanded: 30 → 47 locationsv6
MinorTrial sites expanded: 16 → 30 locationsv5
MinorStudy sites: 2 to 16Start date: Feb 28, 2026 to Mar 10, 2026v4Show 1 more changeShow less
Start date: Feb 28, 2026 to Mar 10, 2026
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 2 · Start date: Jan 30, 2026 to Feb 28, 2026v3Show 2 more changesShow less
Study sites: 0 to 2
Start date: Jan 30, 2026 to Feb 28, 2026
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.